Similar molecular mass does not guarantee the same crystallization behavior.
What the supplied research shows
A physical-chemistry study compared diazepam, nordazepam and tetrazepam in crystalline and amorphous states. Nordazepam showed hydrogen bonding and substantially different transition temperatures. The compounds also differed in recrystallization kinetics despite broadly similar aspects of molecular relaxation.
What it cannot establish
These were material-property measurements, not a comparative human pharmacokinetic trial. Melting point, glass transition and crystallization do not independently establish how much drug a particular formulation delivers or how impaired a patient becomes. Extrapolation requires formulation-specific evidence.
Forensic interpretation and case review
When evaluating a pharmaceutical or seized-material claim, separate molecular identification from physical form and from biological effect. A material can contain the named compound while differing in crystallinity or stability. Conversely, a laboratory solid-state difference does not prove a clinically important dose difference. The paper supports careful characterization and limits simplistic equivalence claims based only on molecular similarity.
Source and related reading
Source: supplied full-text paper, PMC8594866. Findings are paraphrased; the forensic discussion is an interpretation of the evidence.
Related: Cyclodextrin Choice Changed Both Stability and Chiral Recognition of an Oxazepam Derivative.
Leave a Reply